<DOC>
	<DOCNO>NCT00642187</DOCNO>
	<brief_summary>A comparison safety , efficacy budesonide pharmacokinetics currently approve Pulmicort Turbuhaler new version inhaler , adult patient asthma currently treat inhaled steroid . In addition study evaluate functionality new inhaler end intend life .</brief_summary>
	<brief_title>New Version Pulmicort Turbuhaler USA Adults</brief_title>
	<detailed_description />
	<mesh_term>Budesonide</mesh_term>
	<criteria>Males female least 18 year old diagnosis asthma ( defined ATS ) least 6 month . To enter run period , subject also require following : A forced expiratory volume ( FEV1 ) 1 second 60 % 90 % predict normal , airway reversibility least 12 % 0.20 L , use orally inhaled corticosteroid least 3 month prior study . At Visit 2 , subject meet additional entry criterion relate rescue medication use asthma symptom score run period plus visit specific FEV1 requirement assign randomized treatment Life threaten asthma , Two overnight hospitalisation asthma within 1 year emergency room visit asthma within 6 month start study . Use steroid tablet injection month ( 28 day ) prior Visit 1 use asthma medicine ( except rescue medication ) within 2 week prior study . Any acute exacerbation asthma respiratory tract infection within 30 day prior study . Subject must smoke smoke within 6 month study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Pulmicort</keyword>
	<keyword>Turbuhaler</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Flexhaler</keyword>
</DOC>